Idorsia (XSWX:IDIA) Stock Based Compensation: CHF6.5 Mil (TTM As of Mar. 2026)


XSWX:IDIA Idorsia Ltd XSWX:IDIA
48 GF Score
Price CHF6.40
GF Value CHF2.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Idorsia Stock Based Compensation?

Idorsia XSWX:IDIA -3.18% 48 Stock Based Compensation is CHF6.5 Mil as of Mar. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.87 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Idorsia's Stock Based Compensation for the three months ended in Mar. 2026 was CHF2.8 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was CHF6.5 Mil.

Idorsia Stock Based Compensation Related Terms

Idorsia Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Idorsia's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia Stock Based Compensation Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.73 25.85 23.12 11.51 5.70

Idorsia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.93 -0.18 2.30 1.64 2.76
XSWX:IDIA
48GF Score
Idorsia Ltd XSWX:IDIA
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idorsia Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF6.5 Mil.

What does a Stock Based Compensation of CHF6.5 Mil mean?
Idorsia (XSWX:IDIA) has a Stock Based Compensation of CHF6.5 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Idorsia and its competitors.
Is Idorsia's Stock Based Compensation too high?
Idorsia's current Stock Based Compensation is CHF6.5 Mil. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Stock Based Compensation compare to VRTX and REGN?
Idorsia's Stock Based Compensation of CHF6.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Idorsia and its competitors. Idorsia's current Stock Based Compensation is CHF6.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.87, compared to a current price of CHF6.40 — trading 122.8% above its estimated fair value. The current Stock Based Compensation is CHF6.5 Mil. Idorsia's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Stock Based Compensation is CHF6.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Idorsia (XSWX:IDIA) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.40 is trading 122.8% above its estimated GF Value™ of CHF2.87. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for XSWX:IDIA:

  • Stock Based Compensation: CHF6.5 Mil
  • GF Value™: CHF2.87 vs. price of CHF6.40 (122.8% above fair value)
  • GF Score™: 48/100 with 3 warning signs

No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score

Get the complete analysis for XSWX:IDIA

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.40
Price
CHF2.87
GF Value